文献速递基础与转化研究临床试验与 GCP

由MAPK通路汇聚性激活介导的TRK抑制剂耐药

Resistance to TRK inhibition mediated by convergent MAPK pathway activation.
PubMed 文献 · Nat Med · 2019-08-12

TRK融合见于多种癌症并对TRK抑制高度敏感,但初始应答后耐药机制尚不明确。本文报告TRK抑制剂治疗患者及人源模型中出现由趋同激活MAPK通路的基因组改变介导的脱靶耐药,MAPK通路靶向治疗单用或联合TRK抑制可重新获得疾病控制。

要点

  • 已知耐药机制为靶向TRK激酶域突变,本文报告由MAPK通路激活介导的脱靶耐药。
  • MAPK通路靶向治疗单用或联合TRK抑制可重新获得疾病控制。
  • 实验建模提示 upfront 双重抑制TRK与MEK可能延缓易发生MAPK通路激活改变的肿瘤进展。

核心结论

  • 一部分患者会出现由MAPK通路激活介导的TRK抑制脱靶耐药,对临床管理和未来临床试验设计有潜在意义。

研究设计与样本

  • 研究纳入接受TRK抑制剂治疗的患者及患者来源模型,分析耐药机制。

主要发现

  • 在TRK抑制剂治疗患者及患者来源模型中观察到由趋同激活MAPK通路的基因组改变介导的脱靶耐药。
  • MAPK通路靶向治疗单用或联合TRK抑制可重新获得疾病控制。
  • 实验建模提示 upfront 双重抑制TRK与MEK可能延缓易发生MAPK通路激活基因组改变的肿瘤类型的进展时间。

临床怎么用

  • 原文结论未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

TRK fusions are found in a variety of cancer types, lead to oncogenic addiction, and strongly predict tumor-agnostic efficacy of TRK inhibition1-8. With the recent approval of the first selective TRK inhibitor, larotrectinib, for patients with any TRK-fusion-positive adult or pediatric solid tumor, to identify mechanisms of treatment failure after initial response has become of immediate therapeutic relevance. So far, the only known resistance mechanism is the acquisition of on-target TRK kinase domain mutations, which interfere with drug binding and can potentially be addressable through second-generation TRK inhibitors9-11. Here, we report off-target resistance in patients treated with TRK inhibitors and in patient-derived models, mediated by genomic alterations that converge to activate the mitogen-activated protein kinase (MAPK) pathway. MAPK pathway-directed targeted therapy, administered alone or in combination with TRK inhibition, re-established disease control. Experimental modeling further suggests that upfront dual inhibition of TRK and MEK may delay time to progression in cancer types prone to the genomic acquisition of MAPK pathway-activating alterations. Collectively, these data suggest that a subset of patients will develop off-target mechanisms of resistance to TRK inhibition with potential implications for clinical management and future clinical trial design.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Cocco E, Schram AM, Kulick A, et al. Resistance to TRK inhibition mediated by convergent MAPK pathway activation. Nat Med. 2019. PMID: 31406350. doi:10.1038/s41591-019-0542-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。